Hi, what are you looking for?
Jewish Business News
Search results for "Copaxone"
Business
Teva’s Copaxone, a new medication under development for the treatment of multiple sclerosis treatment Copaxone, has gotten closer to getting approval for marketing in...
Business
– A 50% reduction in adverse side-effects was reported with the three-times-a-week 40 mg MS injection. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA;...
Business
– Teva is battling generic versions of the 20 mg and 40 mg dosages of its MS blockbuster. – In the absence of...
Business
– Multiple sclerosis treatment Copaxone accounts for an estimated half of Teva’s profit. – Changes in the multiple sclerosis treatment market, in which...
Court
– Teva confirmed that it will continue to vigorously defend its Copaxone intellectual property rights. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA)...
Business
– Sales of the multiple sclerosis treatment were down 12% in the second quarter. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reported...
Business
– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that the Company has filed a citizen petition (CP) regarding the approvability of purported generic versions of...
Business
– The European Patent Office ruled in favor of Teva in a patent opposition proceeding filed by Synthon and Mylan. – Teva Pharmaceutical...
Money
– Teva investors are concerned about competition to the company’s Copaxone medication now that its patent has expired. Due to its failed attempt recently...
Business
– Mylan CEO Heather Bresch: Teva’s suit against the FDA was simply a desperate, last minute tactic. – – “We continue to see no...